AstraZeneca has acquired Gracell Biotechnologies for $1 billion, with the potential for additional payments based on regulatory milestones. This acquisition will help AstraZeneca address the challenges of cell therapy manufacturing in cancer treatment and expand into autoimmune diseases. Gracell has developed technologies to shorten manufacturing times and improve the effectiveness of cell therapies, including a potential treatment for multiple myeloma. AstraZeneca sees this acquisition as a way to accelerate its cell therapy strategy in hematology and explore the potential for cell therapy in autoimmune diseases. This acquisition follows other partnerships and investments AstraZeneca has made in the field of cell therapy.
Source link
AstraZeneca Goes With Gracell to Gain an Edge in Next-Generation Cell Therapies
